Friday, June 14, 2013

From Duke: Genomic medicine: a decade of successes, challenges, and opportunities

http://www.ncbi.nlm.nih.gov/pubmed/23761042


 2013 Jun 12;5(189):189sr4. doi: 10.1126/scitranslmed.3005785.

Genomic medicine: a decade of successes, challenges, and opportunities.

Source

Institute for Genome Sciences & Policy, Duke University, Durham, NC 27708, USA.

Abstract

Genomic medicine-an aspirational term 10 years ago-is gaining momentum across the entire clinical continuum from risk assessment in healthy individuals to genome-guided treatment in patients with complex diseases. We review the latest achievements in genome research and their impact on medicine, primarily in the past decade. In most cases, genomic medicine tools remain in the realm of research, but some tools are crossing over into clinical application, where they have the potential to markedly alter the clinical care of patients. In this State of the Art Review, we highlight notable examples including the use of next-generation sequencing in cancer pharmacogenomics, in the diagnosis of rare disorders, and in the tracking of infectious disease outbreaks. We also discuss progress in dissecting the molecular basis of common diseases, the role of the host microbiome, the identification of drug response biomarkers, and the repurposing of drugs. The significant challenges of implementing genomic medicine are examined, along with the innovative solutions being sought. These challenges include the difficulty in establishing clinical validity and utility of tests, how to increase awareness and promote their uptake by clinicians, a changing regulatory and coverage landscape, the need for education, and addressing the ethical aspects of genomics for patients and society. Finally, we consider the future of genomics in medicine and offer a glimpse of the forces shaping genomic medicine, such as fundamental shifts in how we define disease, how medicine is delivered to patients, and how consumers are managing their own health and affecting change.

No comments:

Post a Comment